DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Huntington’s Disease” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the Huntington’s disease market,
comprising key marketed and pipeline drugs, clinical trials, upcoming
and regulatory events, recent events and analyst opinion, probability of
success, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts
Key Takeaways
-
The report estimates that in 2017, there were 159,410 prevalent cases
of Huntington’s disease (HD) in adults aged 30 years and older
worldwide, and forecasts that number to increase to 184,950 prevalent
cases by 2026. -
Northern America is estimated to have the highest disease prevalence
(0.0073%), while Asia has the lowest prevalence (0.0004%). -
Teva’s Austedo and Bausch Health’s Xenazine, which target vesicular
monamine transporters, are the only marketed drugs for HD. These drugs
are administered via the oral route. -
The majority of industry-sponsored drugs in active clinical
development for HD are in Phase II, with only one drug in Phase III.
Therapies in mid-to-late-stage development for HD focus on targets
such as lysosomal cysteine transporter, Huntington, SIRT1, vasopressin
receptors, semaphorin 4D/CD100, aryl hydrocarbon receptor,
phosphodiesterase 10a, PPAR delta, and PPAR gamma. The majority of the
pipeline drugs are administered via the oral route, with the remainder
being intrathecal and intravenous formulations. -
The only high-impact upcoming event in the HD space is topline Phase
II trial results for VX15. The overall likelihood of approval of a
Phase I neurodegenerative asset is 7.7%, and the average probability a
drug advances from Phase III is 48.2%. Drugs, on average, take 10.8
years from Phase I to approval, compared to 9.6 years in the overall
neurology space. -
There were 10 licensing and asset acquisition deals involving HD drugs
during 2014-18. The $1,050m exclusive strategic collaboration and
option agreement signed in 2018 between AbbVie and Voyager
Therapeutics for the development and commercialization of vectorized
antibodies directed against tau for the treatment of Alzheimer’s
disease and other neurodegenerative diseases was the largest deal
during the period. -
The distribution of clinical trials across Phase I-IV indicates that
the majority of trials for HD have been in the early and midphases of
development, with 74% of trials in Phase I-II, and only 26% in Phase
III-IV. -
The US has a substantial lead in the number of HD clinical trials
globally, while the UK leads the major EU markets. Clinical trial
activity in the HD space is dominated by completed trials. Pfizer has
the highest number of completed trials for HD, with 12 trials. -
Pfizer leads industry sponsors with the highest number of clinical
trials for HD, followed by Teva.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Subtypes
TREATMENT
Treatment of chorea
Treatment of parkinsonism
Treatment of behavioral and psychiatric dysfunction
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Nerventra for HD (July 31, 2018)
HTT-ASO for HD (March 1, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Two Neurodegenerative Disease Drugs Secure EMA’s Coveted PRIME
Designation
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Takeda Catches Rising Tide Of Antisense Neuroscience R&D
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/38mfi2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs